Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-85
SponsorChina International Neuroscience Institution

About this trial

Background:Preemptive analgesia is the initiation of analgesic regimen before the onset of nociceptive stimulation, preventing the amplification of pain due to peripheral and central sensitization and thereby reducing subsequent pain. Preemptive analgesia of dexmedetomidine (DEX) in the epidural and subarachnoid space can effectively prevent the central sensitization, and significantly reduce the phantom limb pain, residual pain after one year of lower limb amputation.

Objective: To investigate the per-operative effects of DEX preemptive analgesia.

Method:The patients scheduled noncardiac surgery undergoing general anesthesia were selected and divided into DEX group and Placebo group randmized. The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and 15min after induction. The Placebo group was infused with equal amounts of normal saline.The Coprimary efficacy outcome was a composite of analgesia effect, one is the Compliance Rate of IOC2 target in intra-operation, another is the the rate of none-to-slight post-operative pain assessed with the p-NRS≦3 at 12 hours after surgery \[Pain numeric rating scale was assessed with the (Numeric Rating Scale, p-NRS)\].

Eligibility criteria

Qualifiers

18 years to 85 years old,

body mass index (BMI,calculated as weight in kilograms divided by height in meters squared): 18.5~35.

ASA (American Society of Anesthesiologists) Grade I- III;

Scheduled for non-cardiac surgery undergoing general anesthesia

Disqualifiers

disagreed to participate;

body mass index (BMI) of greater 35

American Society of Anesthesiologists (ASA) classification 4 or above;

previous severe central nervous systemheart, liver, kidney or and lung dysfunction ;

Trial design

Treatments tested in this trial

  • Preemptive Dexmedetomidine injection
  • Sodium Chloride 0.9% Inj

Treatment groups

208 Participants
are divided into 2 treatment groups